Agoracom Blog Home

Posts Tagged ‘Hemp’

Spyder Cannabis $SPDR.ca – 5 Essential #Cannabis Trends You Can’t Afford to Miss – #CBD will take center stage $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 2:49 PM on Tuesday, July 23rd, 2019

SPONSOR: Spyder Cannabis Inc. (TSX-V: SPDR) An established chain of high-end vape stores in Ontario, Canada. The company has an aggressive expansion plan already in place that will focus on Canadian retail and US Hemp-Derived kiosks in high traffic areas. Click here for more info.

Spdr logo large
(TSX-V: SPDR)
————————

5 Essential Cannabis Trends You Can’t Afford to Miss

New research indicates these events will drive the global cannabis market.
  • Until recently, the cannabis market was dominated by THC products, but now CBD is on everyone’s lips. What happened? In 2018, two regulatory events changed the direction and growth trajectory for the cannabis market. Troy Dayton and Roy Bingham

Figuring out where the cannabis industry is heading next is no easy task. The industry is filled with a seemingly daily deluge of noise and breaking news. But there are a handful of trends and events you should keep an eye on. Arcview Market Research in partnership with BDS Analytics has discovered key data points that reveal some of the big industry levers shaping things to come.

1. CBD will take center stage.

Until recently, the cannabis market was dominated by THC products, but now CBD is on everyone’s lips. What happened? In 2018, two regulatory events changed the direction and growth trajectory for the cannabis market.

First, the Food and Drug Administration’s (FDA’s) approved GW Pharmaceutical’s seizure medication, Epidiolex, the first CBD pharmaceutical-grade drug. 

Second, hemp (the cannabis plant high in CBD and low in THC) was legalized for commercial production across the U.S. 

Pharmaceutical companies have since unleashed numerous studies and clinical trials — racing to isolate treatments for a diversity of diseases – from cancer to sleep disorders. And, due to less government restrictions placed on CBD, cannabis dispensaries no longer hold domain over the sale of cannabis products. 

Over time, fortune 500 companies will stampede into the CBD market. In many U.S. markets, general retail stores are now free to stock hemp-based products. And as creams, craft beer, and other CBD infused products make their way onto grocery store shelves in growing numbers, licensed dispensaries will be pushed to stay competitive. 

Just how big is the U.S. CBD market expected to get? 

Our research shows that CBD spending will grow from $1.9 billion in 2018 to a forecast of $20.1 billion by 2024. Include THC sales in the number, and the total U.S. cannabinoid market will soar from $10.5 in 2018 to $44.8 billion as we turn the calendar to 2024. 

This is a 49 percent compound annual growth rate forecast for cannabis and hemp-derived CBD products.

2. Eased regulations will be a catalyst for the cannabis market.

Fear of federal prosecution, the inability to easily use every-day banking services (including depositing money), and little clarity around CBD as a food additive, has been deadweights for the U.S cannabis industry. However, two ground-breaking pieces of legislation are working their way through the legislative labyrinth that should remedy these problems.

First is an amendment to the STATES Act that will exempt the state’s legal activities from the Controlled Substances Act (which classifies cannabis as a Schedule 1 substance). The STATES Act would effectively ease federal cannabis prohibition by ceding the regulation of cannabis to the state level. Secondly, the SAFE Banking Act — which would allow federally chartered banks the ability to accept money from state-legal cannabis businesses.

On the CBD front, the FDA is under pressure to regulate and confirm the rules of the game. Once these guidelines are announced, they are likely to be the trigger for mass adoption of CBD.

3. Canada is still a significant player, but there are clouds on the horizon.

Canada’s historic legalization of adult-use cannabis last year quickly spawned the world’s largest cannabis companies. Our research indicates that by 2024, the Canadian adult-use market will expand to almost $4.8 billion from $113.5 million (in the partial year of 2018).

In the short term, limitations on distribution and the marketing of edibles and concentrates are likely to hamper growth. However, regulations are expected to ease in October. But it will take suppliers several months, maybe even years, to catch up with the product selection and branding strategies, which are the chief drivers of U.S. market growth.

The success of the continued retail roll-out and the federal election in October could potentially dampen the Canadian growth story. Should the liberals be ousted at the polling booths, a change in government policy may curtail the growth trajectory.

4. Other countries will get in the game. 

The global expansion of medical cannabis is attracting investor attention. Our research shows that the international markets’ contribution to global legal sales will rise from 4.7 percent to 13.2 percent between 2018 and 2024. That’s a not inconsequential 33 percent compound annual growth rate through the period.

Internationally, Germany leads the pack, making Europe the leading region. But Uruguay’s pioneering legal adult-use, Luxembourg, Mexico, and New Zealand could also have adult-use sales by 2024.

Reforms in Asia and Africa are also afoot. Patients in South Korea and Thailand will gain access to medical cannabis treatments — albeit highly restricted. And Lesotho, South Africa, Zambia, and Zimbabwe are all in various stages of program development.

But, as a consequence of the opening up of these markets, there may be a shift in the migration of production to regions like Africa and Latin America. Canadian LPs could be left with stranded assets

5. Money will flow to M&As, as companies specialize and rationalize operations.

In two short years, an industry starved for funding is now seeing billion-dollar deals. But the availability of money is becoming less significant. Now it’s about how it will be spent.

Vertically integrated companies are buying out other operations for scale, and the start of a trend towards diversification and specialization is underway.

Over the medium term, a second wave of M&A to ‘rationalize assets’ (i.e. match a firm’s investment in various types of assets to its projected requirements, for achieving optimum ROI) may follow. Companies in maturing industries usually work out what they are best at and divest operations to those better suited to operate these.

Once federal prohibition ends, it’s also no stretch to imagine the mainstream industry giants stepping in and buying out cannabis companies. Courageous entrepreneurs will be richly rewarded for having built attractive take-out targets.

Source: https://www.mysanantonio.com/business/article/5-Essential-Cannabis-Trends-You-Can-t-Afford-to-14113323.php

Marijuana Company of America $MCOA Announces Prelaunch of Premier #Cannabis Delivery Service $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:36 AM on Tuesday, July 23rd, 2019
15233 mcoa
MCOA:OTCQB
  • Company began sign-ups for Viva Buds Inc., a cannabis delivery service developed with joint venture partner Natural Plant Extracts of California
  • Viva Buds’ staff and marketing team have successfully initiated the prelaunch for prospective customers ahead of its official 2019 launch date.

ESCONDIDO, Calif., July 23, 2019 — via NetworkWire - MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTCQB: MCOA), an innovative hemp and cannabis corporation, is pleased to announce the prelaunch of cannabis delivery service Viva Buds Inc. in the San Fernando Valley in Los Angeles, California, with sign-ups now available on its website at https://vivabuds.com.

Viva Buds’ staff and marketing team have successfully initiated the prelaunch for prospective customers ahead of its official 2019 launch date. By signing up for free for the Viva Buds prelaunch, customers will have the opportunity to make referrals before the actual launch date. Viva Buds will offer customers a dynamic opportunity to purchase low-cost premium cannabis products and utilize the “call your friend” approach to build their own personal business. Viva Buds will have its own user-friendly app and will utilize its strategic partnership with MassRoots Inc. to reach out to thousands of its social media followers, beginning in the San Fernando Valley.

In March, Natural Plant Extracts of California (“NPE”) and MCOA announced they had established a joint venture to form Viva Buds, sharing the net profits on a 50-50 basis. NPE will manage all operations pertaining to distribution, manufacturing and delivery of cannabis products, and MCOA will provide capital, consulting and marketing services. Additionally, MCOA is the direct owner of 20% of NPE.

“Our management team is excited to provide this innovative opportunity to future customers of Viva Buds in one of the largest U.S. markets for recreational cannabis,” said Mr. Don Steinberg, CEO of Marijuana Company of America.

“We are excited to be a partner in what we believe will be a game changing and disruptive delivery model in the marketplace,” said Mr. Alan Tsai, CEO of Natural Plant Extracts of California. “We offer an incentivized program that is mutually beneficial for our customers as well as the company. We are confident this adds a lot of unique value and will position Viva Buds as a key player in the delivery sector.”

For more information on Viva Buds and to sign up, please visit https://vivabuds.com. Join the live virtual launch party on August 9th, 2019 at http://www.vivabuds.live.

About Marijuana Company of America, Inc.
MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Natural Plant Extracts of California
NPE is a fully licensed cannabis manufacturing, distribution and non-store front retail delivery. The Company has secured its licenses with the state of California and city of Lynwood, CA. For more information about the Company, please visit its website at https://nldistribution.com The owners and founders of NPE are marijuana industry veterans with decades of experience in establishing retail, manufacturing and distribution of cannabis in California, including obtaining the first retail dispensary licenses in Los Angeles, CA.

Legal Status of Cannabis
While legalized in California for recreational and medicinal use, cannabis remains a Schedule 1 drug under the Controlled Substances Act (21 U.S.C. § 811) and illegal under the federal law.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:
[email protected]
888-777-4362

Corporate Communications Contact: 
NetworkWire (NNW)
New York, New York
www.NetworkNewsWire.com 
212.418.1217 Office 
[email protected] 

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Bougainville Ventures $BOG.ca Signs Production Agreement with Co-Packing Company $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 7:22 AM on Tuesday, July 23rd, 2019
681747 5720 copy 2
  • Announced that the board of Directors have approved the terms of a Contract Production Agreement with a Co-packing Company
  • Co-packing Company is a fully-licensed cannabis co-packing and bottling company that operates to GMP standards.

VANCOUVER, British Columbia, July 23, 2019 — BOUGAINVILLE VENTURES INC. (CSE: BOG) (FRA: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Bougainville” or the “Company”) is pleased to announce that the board of Directors have approved the terms of a Contract Production Agreement (the “Production Agreement”) with a Co-packing Company subject to acceptance of final terms, to produce and process our dedicated line of Cannabidiol derived (“CBD”) products which include the proprietary CBD blended, Medium Chain Triglycerides (“MCT”) Oils tincture product for anxiety, energy and sleep recently acquired from the Island Biopharma Inc., acquisition.

The Co-packing Company is a fully-licensed cannabis co-packing and bottling company that operates to GMP standards. The Production Agreement will enable Bougainville to launch its patented line of bio-cannabis MCT Oil tincture products cost effectively. Pursuant to the Production Agreement the co-packing company has agreed to provide product development, manufacturing, and distribution of our CBD blended MCT Oil tincture products for anxiety, energy and sleep. Bougainville Ventures will commit to a minimum purchase order of 1,000 gallons or 56,000 units. Packaging costs are very competitive with industry norms for the nutraceutical and herbal treatment products and the company’s strategy is primarily to sell to the wholesale market first.

According to an estimate from cannabis industry analysts the hemp-CBD market alone could reach $22 billion by 2022. CBD can be used to effectively to treat epilepsy, anxiety, insomnia and chronic pain. The Island Biopharma CBD line is designed to harness the healing power of cannabis without the psychotropic effects of THC.

About the Co-Packing Company

The Co-packing Company is a Canadian-based company, which is engaged in expanding the ancillary side of the cannabis industry. The company offers local and international brands key services, such as formulation, manufacturing, co-packing, and distribution for THC & CBD infused products.

About Bougainville Ventures, Inc.
Bougainville Ventures Inc. is dedicated to rapid growth in production, processing, retail and branding of cannabis and cannabis related products. Currently the company provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. We offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Also, the Company is focused on building a strong presence in the hemp industry with the objective of extracting cannabinoids in both Canada and the United States. Along with our flagship Hemp project in Oregon State and the Greenhouse campus in Washington state, the Company has proprietary formulas for cannabis edibles, topical, and tinctures.

On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.

Andy Jagpal, President and Director

For further information, please contact Andy Jagpal at [email protected]. Please note that our Toll free number has changed to 1-877-517-7816.

http://bougainvilleinc.com/
https://twitter.com/bougainvilleinc

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

North Bud Farms Inc. $NBUD.ca – #Cannabis Countdown: Top 10 #Marijuana Industry News Stories Of The Week, July 22 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 11:41 AM on Monday, July 22nd, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

—————

The Cannabis Investor    July 22, 2019

Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 marijuana industry news stories for the week of July 15th – 21st, 2019.

Without further ado, let’s get started.

10. Medical Cannabis is Gaining Momentum in Asia

With Thailand’s legalization of medical cannabis in February, some experts predict that other Southeast Asian countries may move to decriminalize the plant. If that happens, it could prove a significant opportunity for investors interested in the space.

9. How The New NAFTA Affects The Cannabis Industry

At the end of 2018, Canada, the United States, and Mexico agreed on new terms to replace the North American Free Trade Agreement (NAFTA). The new treaty, the Canada-United States-Mexico Agreement (CUSMA), establishes updated legal language surrounding trade tariffs, environmental and labour regulations, and intellectual property protections.

It was only just last year that Canopy Growth CGC 2.14% completed the first legal export of medical cannabis to the United States. As the world waits for the United States and Canada to follow Mexico in ratifying the new trade agreement, this is what cannabis investors should know about how the deal affects the marijuana industry.

8. Top 10 Hip Hop Artists Looking to Capitalize on the Cannabis Boom A$AP

Hip-hop star A$AP Rocky made global headlines in July because of an altercation and is now locked up Sweden. Thousands of fans and even politicians like President Trump are calling for his release.

Like many other rappers, A$AP Rocky’s fortunes are not tied up only in lyrics. These famous artists aren’t just signing record deals anymore. Top rappers are now signing lucrative weed contracts.

Now that cannabis is going mainstream, let’s take a look at the top ten hip hop artists who are capitalizing on the green rush.

7. Imports of Medical Marijuana into Germany Surge in Second Quarter

Germany imported almost 2,500 kilograms (5,500 lbs) of medical cannabis flower for pharmacy dispensing during the first half of 2019.

That’s almost as much as the country imported in all of 2018, a sign that the expected growth in the market is coming to fruition.

6. Final Chance to Tell The FDA How it Should Regulate CBD

U.S. health authorities are taking final comments from the public on how to regulate over-the-counter cannabis extracts such as CBD. The suggestions are due to the U.S. Food and Drug Administration (FDA) by midnight ET Tuesday, July 16, on how the agency should regulate cannabis-derived products.

The FDA has vowed to expedite its review of cannabis-derived compounds because of a surge in CBD products hitting the market. The agency now says it will have an update on the review by late summer or early fall.

5. Ohio Lawmakers Vote to Decriminalize CBD Oil, Hemp Products

The Ohio House on Wednesday voted 88-3 in favor of legislation that would move Ohio closer to decriminalizing hemp and hemp products, including CBD oil. Under current state law, hemp is considered a Schedule I drug because it — like marijuana — comes from the cannabis plant. However, hemp contains a low concentration of THC, marijuana’s psychoactive stimulant.

The bill would exclude hemp and its products from the definition of marijuana that the state uses to enforce controlled substance laws, and it would further prohibit the state’s Board of Pharmacy from listing hemp as a controlled substance.

4. Aurora Sole Winner of Italian Medical Cannabis Tender, But Average Price is Low by Most Standards

Aurora Deutschland – the German subsidiary of Aurora Cannabis ACB 3.88% â€“ won all three “lots”to supply Italy with a total of 400 kilograms (880 lbs) of medical marijuana over two years, the Italian government announced.

But the award may come at a cost for Aurora as the average price it offered – 1.73 euros per gram ($1.94) – was less than half the tender reference prices and only slightly above the company’s latest reported average “cash cost of sales per gram of dried cannabis sold.”

3. Meet The Man Behind The CannTrust Meltdown

It appears clear that CannTrust’s CTST 2.41% widely reported non-compliance violations with Health Canada are the result of a whistle-blowing former employee.

On June 15, Fenwick resident Nick Lalonde, who worked at the Balfour Street site for almost two years, had emailed the Voice and several Health Canada employees with various allegations of infractions— including cannabis being grown in unlicensed areas.

2. Here’s Why Jay-Z’s New Cannabis Partnership is a Major Win for the Industry

If you weren’t already convinced that cannabis has gone mainstream — you will be now.

American rapper, business mogul, and all-around cultural giant, Shawn “Jay-Z” Carter, just announced a multi-year partnership with this leading California cannabis company. In addition to helping strengthen the company’s bottom line, Jay-Z will also look to create opportunities for those hurt by the prohibition of cannabis.

1. Sluggish U.S. Senate Awakens, Cannabis Banking Access is on the Way

When it comes to bringing cannabis banking out of the informal cash exchange world and into America’s banking sector with Senate’s support, the train is finally leaving the station. The Senate has scheduled a hearing next week to discuss cannabis companies and their access to legitimate banking.

Open and fair banking access for cannabis companies in the United States will play a crucial role in the industry’s expansion and will eventually lead to the implementation of interstate and online cannabis commerce.

Source: https://www.benzinga.com/markets/cannabis/19/07/14109951/cannabis-countdown-top-10-marijuana-industry-news-stories-of-the-week-july-22

Spyder Cannabis $SPDR.ca Receives Approval on Development Permit for its Flagship #Cannabis Store in Calgary, Alberta $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:54 AM on Monday, July 22nd, 2019
Spdr logo large
  • Announced that it has received approval on their development permit for a flagship retail location in the heart of Calgary
  • Spyder has now been accepted by Alberta Health Services and will begin construction in the coming weeks.

Vaughan, Ontario–(July 22, 2019) – Spyder Cannabis Inc.TSXV : SPDR) (“Spyder“), an established Canadian cannabis and vape retail operator, is pleased to announce that it has received approval on their development permit for a flagship retail location in the heart of Calgary.

In July 2018, Spyder acquired a lease for an approximately 8,000 square feet location in Calgary, Alberta, which Spyder intends to operate both as its flagship retail location, and as a central distribution hub for its product offerings. Spyder had received a municipal development and building permit in late 2018, subject to receiving a variance from the Province of Alberta. Spyder has now been accepted by Alberta Health Services and will begin construction in the coming weeks.

“We have built our Spyder retail brand to provide a superior customer experience and have focused on locations with high foot traffic in urban centres and destinations” said Dan Pelchovitz, Spyder President and CEO. “This will give us plenty of room to present an engaging retail experience, rooted in a customer centric retail concept with unique design, warm features, complete with well trained and knowledgeable staff”

This location brings Spyder’s total retail to 6 locations across Ontario and Alberta. This number is expected to grow over the coming months as the Spyder is currently negotiating additional leases with the intention of submitting applications for retail licenses. Spyder is executing an aggressive expansion plan to create a significant retail brand in the Canadian and U.S. adult use market. It is committed to acquiring and developing prime North American retail locations and continuing to expand the reach of its brand.

About Spyder

Founded in 2014 Spyder is an established chain of three high-end vape stores, and two cannabis accessory stores, in Ontario, with locations in Woodbridge, Scarborough, Burlington, Pickering and Niagara Falls. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding eCig and vapes company and is pursuing expansion into the legal cannabis and hemp derived market. Spyder has developed a scalable retail model with plans to create a significant footprint with targeted and disciplined retail distribution strategy focusing on Canadian retail and U.S. boutique retail and kiosks in high traffic peripheral areas.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: (905) 265-8273
Email: [email protected]

Bullseye Corporate
Crystal Quast
Bullseye Corporate
[email protected]

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur..

These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Any number of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46417

North Bud Farms Inc. $NBUD.ca – Booming Demand for #CBD Is Making Hemp the #Cannabis Cash Crop $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 11:28 AM on Thursday, July 18th, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

—————

Booming Demand for CBD Is Making Hemp the Cannabis Cash Crop

  • Players in the $340 billion global cannabis market are turning their attention to weed’s less-regulated cousin, hemp.
  • Hemp is a strain of cannabis whose fibers have traditionally been used in textiles and rope, and farmers can grow it even in countries with strict drug laws because it has different properties from marijuana.

By Craig Giammona and Bruce Einhorn

Mention legal cannabis, and many people think of the weed stores that have sprung up in Boston, Denver, Seattle, and other major U.S. cities. Inside, infused brownies and vape pens are sold next to branded joints and neatly packaged bags of marijuana presented in a way that wouldn’t be out of place in any American mall. In Canada you can even order pot through the mail, and some of the world’s alcohol giants have set up shop there to develop weed beer.

But the business of getting people high is only part of the cannabis craze. Marijuana is still banned for recreational use across much of the world, and even medical access, while expanding, is restricted in most countries. So players in the $340 billion global cannabis market are turning their attention to weed’s less-regulated cousin, hemp.

Marijuana 101

• THC: Tetrahydrocannabinol is the chemical in marijuana that produces a high.
• CBD: Cannabidiol, a nonintoxicating compound, can be derived from hemp and marijuana.
• Cannabis: Hemp and marijuana are both types of cannabis. Hemp faces fewer restrictions because it’s generally cultivated with lower levels of THC.

Hemp is a strain of cannabis whose fibers have traditionally been used in textiles and rope, and farmers can grow it even in countries with strict drug laws because it has different properties from marijuana. Most important to law enforcement officials, it’s low in THC, the compound that gets you stoned. But businesses are buzzed about its other defining characteristic: a higher concentration of cannibidiol, or CBD, a nonpsychoactive chemical at the center of a wellness trend sweeping the U.S. and expanding worldwide.

Global Market Share and Sales by Hemp Product Category in 2018

Data: Hemp Business Journal

CBD is being pitched as an all-natural way to alleviate ailments including pain, inflammation, anxiety, and insomnia. Despite a paucity of science to back up such claims, CBD has become a coveted ingredient in a host of consumer products, from skin lotions to sparkling water to tinctures to dog biscuits. The surge in demand is fueling a global Green Rush, even in countries where a legal market for cannabis products was unthinkable just a few years ago. “We are getting phone calls from big pharma groups in Asia, all parts of the world: ‘Can you get product? Can you supply to us?’ ” says Glenn Davies, chief executive officer of industrial hemp grower CannAcubed Pte. The Singapore-based startup planted its first commercial hemp crop in May in China’s Yunnan province. “It’s all about hemp.”

One of the first plants ever domesticated, cannabis was used for thousands of years for fiber, food, and medicine. Yet for the better part of the last century it’s largely been traded on the black market, banned in many countries alongside cocaine, heroin, and other controlled substances. Much of that bad-boy reputation faded last year when Congress legalized CBD in the U.S.

Researchers estimate the market for CBD in the U.S. alone could be worth almost $24 billion by 2023. In Canada sales of legal cannabis may reach $4.7 billion by that time, up from about $570 million last year, according to BDS Analytics. Annual sales of CBD could potentially be larger than those of marijuana, analysts say, because of the large number of products in which it can be used.

U.S. Hemp Imports by Source Region, 2017

Data: Hemp Business Journal

Investors are pouring money into massive CBD extraction facilities and processing plants in the U.S., hoping to be ready when Coca-Cola Co., Procter & Gamble Co., and other consumer giants finally embrace cannabis. Colorado CBD company Mile High Labs has developed technology to remove unrefined hemp extract from the plant, and it recently paid $18.8 million for a 400,000-square-foot former Novartis factory where it will make products such as lotions and tinctures.

American farmers are plowing into the hemp industry in Colorado, Kentucky, Montana, Oregon, and other states. This year, more than 200,000 acres of hemp are licensed to be planted in the U.S., up from roughly 25,000 two years ago. Asia, which has a long history with natural medicines, is also seeing growing interest in cannabis. In 2017, China planted at least 113,000 acres of hemp, according to New Frontier, an industry researcher. Cultivation is also on the rise in Colombia, Greece, Jamaica, and even the southern African nation of Lesotho. “You get the domino effect: The farmer in Bulgaria looking across at peers in Greece and asking questions, putting pressure on the government to make similar steps,” says Shane MacGuill, an analyst at Euromonitor International. “The more it happens, the more quickly we get the spread of cultivation.” Hemp producers in Asia and other lower-cost regions could ultimately undercut U.S. farmers, especially as the quality of their crop improves and a global market takes shape, with hemp moving freely across borders like any other agricultural commodity. In June, CannAcubed leased two factories in Yunnan, one of only three Chinese provinces that allows the production of hemp; it plans to expand them into CBD research and extraction facilities.

Not everyone is so sanguine. Mark Mees, CEO of Setek Therapeutics in New Zealand, sees cannabis becoming another agricultural commodity, with prices racing downward. And Mees, whose company has a license to grow medical marijuana in the country, says the CBD business has been overhyped. “You get a few hippies and that’s great. One thing that’s missing is old-fashioned business sense,” he says. “We will see a train wreck of small companies that completely underestimated the costs and the complexity of what they’re trying to do.”

Global Hemp Sales

Data: Hemp Business Journal

Restrictions on medical pot are loosening globally. More than 50 countries, including Australia, Brazil, and Germany, have legalized access to medicinal cannabis, according to Bloomberg Intelligence, making it easier for farmers to plant hemp or marijuana. But dealing with pot can still be tricky. In New Zealand, companies can grow medical weed only for research, though the government is working on a commercialization plan. Cannasouth Ltd. has struggled as New Zealand’s sole publicly traded cannabis company, with its shares falling 24% since its IPO on June 19.

As countries remove restrictions, cannabis prices could fall. That would hurt farmers, but potentially boost the profit margins of companies using cannabis as an ingredient. Worries about an industry bubble surfaced earlier this year in China after investors flocked to companies linked to cannabis. Regulators sought to rein in the enthusiasm, with the Shenzhen Stock Exchange telling companies to warn investors about uncertainties facing their industrial cannabis projects.

Canadian farmers have seen a hemp boom-and-bust cycle before. The crop was legalized for production in 1998, and farmers benefited when hemp seed took off as a health-food product. Business peaked in 2015 as South Korean demand drove the market. But China, becoming a cheaper supplier for Korean buyers, sucked profit away from Canada’s hemp-seed farmers. Still, that hasn’t deterred Canadians from trying to cash in on CBD. This year, hemp acreage in the country is expected to more than double, to about 82,000 acres.

In Asia, CannAcubed’s Davies is also unfazed by the risks. “Everybody is trying to have the same outcome and objective: Get this industry moving,” he says. —With Ashley Robinson BOTTOM LINE – Fueled by growing demand for CBD as a health-enhancing ingredient in foods and beauty products, sales of the cannabis derivative could hit $24 billion in the U.S. by 2023.  

Source: https://www.bloomberg.com/news/articles/2019-07-18/booming-demand-for-cbd-is-making-hemp-the-cannabis-cash-crop

Spyder #Cannabis $SPDR.ca Signs Supply Agreement For Premium #Hemp Products And Unveils Their New SPDR(R) Line $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:39 AM on Thursday, July 18th, 2019
Spdr logo large
  • Announced that it signed its first hemp agreement for the supply of full spectrum products to support Spyder’s debut of a hemp infused product line to be sold across the U.S. under its SPDR(R) brand
  • Spyder is expanding its chain of hemp-infused medical and lifestyle product shops with their new brand
  • Initial launch will feature four distinct hemp-derived products; Balms at 125mg and 500mg strength, tinctures at 300mg, 500mg and 1,000mg strength, soft gel capsules at 15mg strength and a pet line starting with tinctures at 300 mg strength

Vaughan, Ontario–(July 18, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder“), an established cannabis and vape retail operator intending to become one of North America’s leading hemp-infused medical and lifestyle company, today announced that it signed its first hemp agreement for the supply of full spectrum products to support Spyder’s debut of a hemp infused product line to be sold across the U.S. under its SPDR(R) brand.

Spyder is expanding its chain of hemp-infused medical and lifestyle product shops with their new brand called SPDR (R). These boutique shops will stock Spyder’s SPDR (R) branded hemp infused products developed for an aging, health and wellness demographic. Spyder will offer a wide array of hemp-infused product offerings including; muscle balm, face oil, body lotion and bath salts, as well as hemp-infused tinctures, capsules and sprays. In addition, hemp is a natural source of CBD, the non-intoxicating component of cannabis that can be used for health and wellness purposes in jurisdictions where legally permitted.

The hemp industry is booming and has the potential to become a $22 billion business by 2022, according to cannabis-focused research firm Brightfield Group. “Spyder plans on executing an aggressive expansion plan to create a significant retail brand in the U.S. hemp market,” stated Daniel Pelchovitz, CEO and President of Spyder. “We are very pleased to partner with this producer which will provide the product formulation and packaging to help create a premium product line for consumers across the U.S.”

The initial launch will feature four distinct hemp-derived products; Balms at 125mg and 500mg strength, tinctures at 300mg, 500mg and 1,000mg strength, soft gel capsules at 15mg strength and a pet line starting with tinctures at 300 mg strength.

About Spyder Cannabis

Founded in 2014 Spyder is an established chain of three high-end vape stores, and two cannabis accessory stores, in Ontario, with locations in Woodbridge, Scarborough, Burlington, Pickering and Niagara Falls. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding eCig and vapes company and is pursuing expansion into the legal cannabis and hemp derived market. Spyder has developed a scalable retail model with plans to create a significant footprint with targeted and disciplined retail distribution strategy focusing on Canadian retail and U.S. boutique retail and kiosks in high traffic peripheral areas.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: (905) 265-8273
Email: [email protected]

Bullseye Corporate
Crystal Quast
Bullseye Corporate
[email protected]

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur..

These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Any number of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46346

Marijuana Company of America $MCOA Launches New #CBD-Infused Cosmetic Product #hempSMART; Body Cream $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:31 AM on Thursday, July 18th, 2019

Company is expanding its product line in response to higher global market demand

15233 mcoa
  • Announced that the Company’s hempSMART™ brand has launched its new product called hempSMART Body Cream™.
  • Each bottle of hempSMART Body Cream is formulated with 300mg of organically grown, full spectrum, non-psychoactive cannabinoid (CBD), derived from industrial hemp.

ESCONDIDO, Calif., July 18, 2019  MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTCQB: MCOA), an innovative hemp and cannabis corporation, today announced that the Company’s hempSMART™ brand has launched its new product called hempSMART Body Cream™.

Each bottle of hempSMART Body Cream is formulated with 300mg of organically grown, full spectrum, non-psychoactive cannabinoid (CBD), derived from industrial hemp. This revolutionary nourishing topical formula combines premium CBD oil with a unique blend of synergistic Ayurvedic herbs and botanicals.

“The new hempSMART Body Cream is a major advancement in the wellness arena,” said Paula Vetter, holistic nurse practitioner, certified herbalist, and Chair of the hempSMART Medical Advisory Board. “The cream is completely free of toxins that are commonly found in many skin care products and absorbed through the skin and into the blood stream. Instead, hempSMART’s Body Cream is a topical wellness solution that sets a new standard in the industry by improving the overall health of skin with each use.”

hempSMART Body Cream takes a quantum leap beyond hydration to replenish, restore and rejuvenate skin cells for improved elasticity, supple texture and healthy radiance. This innovative formula is rich in omega 3, 6, 7 and 9, along with naturally occurring plant ceramides to build a strong and vibrant cellular matrix deep within skin layers. Premium botanicals include organic aloe, sacha inchi oil, argan kernel oil, macadamia nut oil, rose hip seed oil, frankincense, tulsi, pomegranate seed oil, ashwagandha, turmeric oil, coconut oil and sea buckthorn oil.

“Our Company continues to dedicate itself to providing our customers with all-natural products infused with the highest quality CBD oil found on the market,” said MCOA’s CEO, Don Steinberg. “We are excited by this launch and anticipate great customer feedback.”

The hempSMART product line distinguishes itself from competitors through its premier quality extracts from industrial hemp plants grown specifically to provide the highest concentration of CBD. The exclusive hempSMART line currently includes six popular products: hempSMART Brain™, hempSMART Drops™, hempSMART Face™, hempSMART Pain™, hempSMART Pain Cream™, and hempSMART Pet Drops™. These products have all been carefully formulated to provide the desired “Entourage Effect,” which is the most natural interaction the human body can have with CBD.

About Marijuana Company of America, Inc.
MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Legal Status of Cannabis
While legalized in California for recreational and medicinal use, cannabis remains a Schedule 1 drug under the Controlled Substances Act (21 U.S.C. § 811) and illegal under the federal law.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:
[email protected]
888-777-4362
Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com 
212.418.1217 Office 
[email protected] 

For more information, please visit the Company’s websites at:

Empower Clinics $CBDT.ca Provides Corporate Update – Consolidation Shows 350% Growth $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:31 AM on Wednesday, July 17th, 2019
Epw logo1
  • First Signed Franchise Application 
  • Consolidation Shows 350% Growth
  • Retail Product Kiosks Launched 

VANCOUVER, July 17, 2019  - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, is pleased to announce it has received it’s first signed franchise application and that the Company has filed on sedar.com, the Business Acquisition Report (BAR) for the Sun Valley Certification Clinics Holdings LLC acquisition.

The Company continues to reach a number of important milestones on its path forward, as a global health and wellness company, serving the needs of patients through its network of physician-staffed health and pain management clinics, formulating CBD based products and developing its first CBD extraction facility.

HIGHLIGHTS

  • First Signed Franchise Application The Company’s Sun Valley Health division has received its first signed application for a Sun Valley Health Franchise in the U.S., marking an important milestone that the Company expects has the potential to change the landscape of how patients and consumers will access qualified and approved physicians for consultations for alternative health and treatment options throughout the country.

  • Company Files Sun Valley Business Acquisition Report (BAR) The Company has filed the required Business Acquisition Report (BAR) for the Sun Valley Certification Clinics Holdings LLC acquisition closed April 30th, 2019. The report highlights the audit of Sun Valley and the consolidation of Empower Clinics and Sun Valley financial results, if combined for full year 2018 and 1Q 2019.

  • Consolidation Shows 350% Growth The Business Acquisition Report (BAR) after the completion of the 2018 Sun Valley audit shows there would be a 350% growth in Company revenues under consolidation. 1Q 2019 consolidated results show there would be in excess of 500% growth under consolidation.

“The Sun Valley acquisition is accretive to the Company in so many tangible ways, through increased brand awareness, to bringing onboard a talented energetic team, and providing even greater access to patients,” said Steven McAuley, CEO of Empower. “With the release of the BAR, we are now able to demonstrate the significant financial benefit these assets provide to our growing company.”

HIGHLIGHTS Continued

  • Retail Product Kiosks Launched The Company has completed the set up of its first full retail product kiosk and display area in one of its key Phoenix clinics, that includes over (40) product SKU’s, including the CBD lines of Sollievo, Sun Valley Science and a variety of premium health supplements.

  • Extraction Facility Progress The Company has submitted its hemp-handlers license application to the Oregon Department of Agriculture and paid the required fees to ensure the new 5,000 sq. ft. facility in Sandy, OR will be fully compliant with all Oregon regulations and permit requirements. Security systems and IT networks have been installed in preparation for the next phase of build-out and extraction equipment installation.

  • CBD Market Demand The passing in the United States of the US$867 billion Agriculture Improvement Act (the “Farm Bill“) has legalized hemp and hemp-based products. This has created an opportunity for the production and sale of a variety of CBD-based products that can provide genuine help and effective relief to millions of people suffering from a variety of qualifying conditions. Recent reports and studies indicate the approval of the Farm Bill could create a US$20 billion industry by 2022.

ABOUT EMPOWER

Empower is a leading multi-state operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. Operating as a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company can produce and package its proprietary line of cannabidiol (CBD) based products and distribute through company owned and franchised clinics, with wholesale partnerships, online and with retailers nationwide.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation by Q2 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2019/17/c6639.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019

Bougainville Ventures $BOG.ca Oregon Hemp Farm Signing LOI with USA Hemp to Process 298 Acres of #Hemp $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 7:25 AM on Wednesday, July 17th, 2019
681747 5720 copy 2
  • Announced that its U.S. Subsidiary Worm Casting Farms Inc. has signed a LOI with USA Hemp to process its Hemp derived wet biomass Hemp from its 298 Acre Hemp Farm in Oregon State.
  • USA Hemp possesses 298 Acres of hemp to process for Worm Casting Farms with an estimated 4,250,000 lbs of Hemp derived wet biomass per harvest.

VANCOUVER, British Columbia, July 17, 2019 — BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE: BOG) (8BV-FF:Frankfurt Stock Exchange) – The Company is pleased to announce that its U.S. Subsidiary Worm Casting Farms Inc. (Worm Casting Farms) has signed a LOI with USA Hemp to process its Hemp derived wet biomass Hemp from its 298 Acre Hemp Farm in Oregon State.

USA Hemp Processing Agreement

Worm Casting Farms intends to enter into a Hemp Processing Agreement with USA Hemp to process wet biomass. The percentage split will be determined in a Definitive Agreement entered into after completion of a due diligence period. Both parties will receive dividends to be realized from the business operations of the Hemp Process Agreement.

USA Hemp possesses 298 Acres of hemp to process for Worm Casting Farms with an estimated 4,250,000 lbs of Hemp derived wet biomass per harvest. Worm Casting Farms will invest approximately $2,500,000 USD in processing equipment that will include; a harvester, shredder, separator, dryer, an extraction & distillation unit, and testing facility. A detailed description will be provided in the Definitive Agreement.

10 Acre Oregon Hemp Farm – Update

Further to the Company’s news release dated July 11, 2019, announcing the contracting of a mobile processing unit (the “Mobile Processing Unit”), the Company is pleased to report that the Mobile Processing Unit will be arriving at the farm on July 22, 2019. The Mobile Processing Unit will process dried biomass hemp from last year’s harvest. The total amount to be processed is approximately 1,700 lbs of bio-mass and processing take approximately 5 days. The anticipated value of the crop is $250,000 USD in gross revenue and the Company anticipates a net revenue before taxes $200,000 USD.

Island Biopharma Inc., — Update

Further to the Company’s news release dated June 11, 2019, the Company has signed a definitive agreement (the “Biopharma Definitive Agreement”) to complete the acquisition of Island Biopharma Inc. (“Biopharma”). Biopharma has developed a dedicated line of Cannabidiol derived (“CBD”) products which include a proprietary CBD blended tincture product with three specific recipes for anxiety, energy and sleep.

According to an estimate from cannabis industry analysts the hemp-CBD market alone could reach $22 billion by 2022. CBD can be used to effectively to treat epilepsy, anxiety, insomnia and chronic pain. The Island Biopharma CBD line is designed to harness the healing power of cannabis without the psychotropic effects of THC.

Pursuant to the Biopharma Definitive Agreement the Company will acquire 100% of Biopharma assets and current inventory. In return for total consideration consisting of 10 million common shares of Bougainville at a deemed price of CAD$0.07 per share equivalent to CDN$700,000. Biopharma will contribute operational expertise, exclusive licenses for products marketed in North America supported by an intellectual property licensing agreement, and exclusivity for all current and future technology for oil extraction in North America, which will include sourcing of ingredients, nutritional chart, shelf-life, as well as cost of ingredients and contacts. The final evaluation was determined by an independent third-party evaluator.

About Island Biopharma Inc.

Biopharma has developed CBD blended formulas for tincture product with three specific recipes for anxiety, energy and sleep. The philosophy of Biopharma is to create products using the highest quality of bio-active ingredients, and oil extraction methods that preserve the essence of the cannabis plant. Biopharma has studied plant genetics for their therapeutic effects by incorporating modern research techniques and by analyzing the healing and therapeutic benefits of each strain giving the company a huge range of combinations and therapeutic benefits for specific ailments.

About Bougainville Ventures, Inc.
Bougainville Ventures Inc. is dedicated to rapid growth in production, processing, retail and branding of cannabis and cannabis related products. Currently the company provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. We offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Also, the Company is focused on building a strong presence in the hemp industry with the objective of extracting cannabinoids in both Canada and the United States. Along with our flagship Hemp project in Oregon State and the Greenhouse campus in Washington state, the Company has proprietary formulas for cannabis edibles, topical, and tinctures.

On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.

Andy Jagpal, President and Director

For further information, please contact Andy Jagpal at [email protected]. Please note that our Toll free number has changed to 1-877-517-7816.

http://bougainvilleinc.com/
https://twitter.com/bougainvilleinc

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.